InnovAge Holding (INNV) Stock Overview
Manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for INNV from our risk checks.
INNV Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
InnovAge Holding Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.35 |
| 52 Week High | US$10.69 |
| 52 Week Low | US$3.13 |
| Beta | 0.49 |
| 1 Month Change | -7.55% |
| 3 Month Change | -17.42% |
| 1 Year Change | 81.93% |
| 3 Year Change | 16.11% |
| 5 Year Change | -66.42% |
| Change since IPO | -69.63% |
Recent News & Updates
Recent updates
INNV: Updated Modeling And 2026 Guidance Will Shape Balanced Risk Reward Outlook
Analysts have raised their price target on InnovAge Holding to $7 from $5, reflecting updated modeling related to fair value, discount rate, growth expectations, profit margins, and future P/E assumptions. Analyst Commentary JPMorgan raised its price target on InnovAge Holding to US$7 from US$5 after updating its model, while maintaining an Underweight rating on the stock.INNV: Updated Modeling And 2026 Guidance Will Likely Limit Future Share Upside
Analysts raised their price target on InnovAge Holding to $7 from $5, citing updated company modeling as the key driver of the change. Analyst Commentary The move to a US$7 price target signals that at least one major firm sees enough change in the underlying assumptions to justify a higher valuation for InnovAge Holding, even while keeping a cautious stance on the stock.INNV: Updated Modeling And 2026 Guidance Will Likely Temper Upside Expectations
Analysts have raised their price target on InnovAge Holding to $7 from $5, reflecting updated modeling assumptions that incorporate refined views on fair value, discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary JPMorgan's updated price target signals a fresh look at InnovAge Holding's valuation framework, even as the firm maintains an Underweight stance.INNV: Raised Outlook And Model Assumptions Will Likely Prove Overly Optimistic
Analysts have lifted their price target on InnovAge Holding to $7 from $5, reflecting updated models that refine assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts view the lift in the price target to $7 as a sign that updated assumptions on fair value and discount rates support a higher implied equity valuation.INNV: Raised Outlook And P/E Assumptions Will Likely Prove Overly Optimistic
Analysts have lifted their price target on InnovAge Holding to $7 from $5, reflecting updated modeling assumptions around fair value, discount rate, revenue growth, profit margin and future P/E that collectively support a modestly higher valuation framework. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a US$7 price target as recognition that updated fair value work supports a somewhat higher valuation range than before.InnovAge: The Headwinds Are Priced In, The Growth May Not Be
Summary InnovAge Holding Corp. delivers strong operational execution, driving significant revenue and margin expansion through its PACE model for elderly care. INNV’s revenue rose 14.7% year-over-year, fueled by participant growth and capitation rate adjustments across established centers. Disciplined cost management and SG&A reductions have expanded center-level contribution margin to 22% and adjusted EBITDA margin to 9.2%. Despite Medicaid eligibility headwinds, INNV’s improved processes and in-house pharmacy transition support a bullish outlook on sustainability and leverage. Read the full article on Seeking AlphaINNV: Future Margin Assumptions Will Likely Prove Overly Optimistic
Analysts have revised their price target on InnovAge Holding, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Together, these factors result in a new target of $7.00, up from $5.00.Earnings Beat: InnovAge Holding Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
InnovAge Holding Corp. ( NASDAQ:INNV ) investors will be delighted, with the company turning in some strong numbers...InnovAge Holding Corp.'s (NASDAQ:INNV) Price In Tune With Revenues
It's not a stretch to say that InnovAge Holding Corp.'s ( NASDAQ:INNV ) price-to-sales (or "P/S") ratio of 0.9x right...InnovAge Holding (NASDAQ:INNV) Might Be Having Difficulty Using Its Capital Effectively
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...InnovAge Holding Corp. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
As you might know, InnovAge Holding Corp. ( NASDAQ:INNV ) just kicked off its latest quarterly results with some very...Is InnovAge Holding (NASDAQ:INNV) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Improved Revenues Required Before InnovAge Holding Corp. (NASDAQ:INNV) Stock's 32% Jump Looks Justified
InnovAge Holding Corp. ( NASDAQ:INNV ) shareholders would be excited to see that the share price has had a great month...Health Check: How Prudently Does InnovAge Holding (NASDAQ:INNV) Use Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Expanding US Senior Care Integration Will Drive Healthcare Transformation
Enrollment growth and efficient geographic expansion are positioning the company for sustained revenue gains and scalable growth.After Leaping 36% InnovAge Holding Corp. (NASDAQ:INNV) Shares Are Not Flying Under The Radar
InnovAge Holding Corp. ( NASDAQ:INNV ) shares have had a really impressive month, gaining 36% after a shaky period...Is InnovAge Holding (NASDAQ:INNV) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Investors Aren't Entirely Convinced By InnovAge Holding Corp.'s (NASDAQ:INNV) Revenues
InnovAge Holding Corp.'s ( NASDAQ:INNV ) price-to-sales (or "P/S") ratio of 0.6x may look like a pretty appealing...Investors Aren't Entirely Convinced By InnovAge Holding Corp.'s (NASDAQ:INNV) Revenues
It's not a stretch to say that InnovAge Holding Corp.'s ( NASDAQ:INNV ) price-to-sales (or "P/S") ratio of 1.1x seems...Is InnovAge Holding (NASDAQ:INNV) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...InnovAge Holding Corp.'s (NASDAQ:INNV) Shares Leap 30% Yet They're Still Not Telling The Full Story
InnovAge Holding Corp. ( NASDAQ:INNV ) shares have had a really impressive month, gaining 30% after a shaky period...Sentiment Still Eluding InnovAge Holding Corp. (NASDAQ:INNV)
It's not a stretch to say that InnovAge Holding Corp.'s ( NASDAQ:INNV ) price-to-sales (or "P/S") ratio of 0.8x right...InnovAge Holding (NASDAQ:INNV) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Market Still Lacking Some Conviction On InnovAge Holding Corp. (NASDAQ:INNV)
There wouldn't be many who think InnovAge Holding Corp.'s ( NASDAQ:INNV ) price-to-sales (or "P/S") ratio of 1.1x is...InnovAge Holding Corp.'s (NASDAQ:INNV) Intrinsic Value Is Potentially 73% Above Its Share Price
Key Insights The projected fair value for InnovAge Holding is US$11.07 based on 2 Stage Free Cash Flow to Equity...Shareholder Returns
| INNV | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 1.9% | -2.3% | 2.5% |
| 1Y | 81.9% | 13.3% | 26.4% |
Return vs Industry: INNV exceeded the US Healthcare industry which returned 16.3% over the past year.
Return vs Market: INNV exceeded the US Market which returned 28.7% over the past year.
Price Volatility
| INNV volatility | |
|---|---|
| INNV Average Weekly Movement | 7.8% |
| Healthcare Industry Average Movement | 7.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: INNV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: INNV's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 2,440 | Patrick Blair | www.innovage.com |
InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. It manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. The company also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to and from the PACE center and third-party medical appointments; and care management.
InnovAge Holding Corp. Fundamentals Summary
| INNV fundamental statistics | |
|---|---|
| Market cap | US$977.30m |
| Earnings (TTM) | -US$11.61m |
| Revenue (TTM) | US$949.17m |
Is INNV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INNV income statement (TTM) | |
|---|---|
| Revenue | US$949.17m |
| Cost of Revenue | US$300.41m |
| Gross Profit | US$648.76m |
| Other Expenses | US$660.37m |
| Earnings | -US$11.61m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.086 |
| Gross Margin | 68.35% |
| Net Profit Margin | -1.22% |
| Debt/Equity Ratio | 22.4% |
How did INNV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/26 10:08 |
| End of Day Share Price | 2026/05/26 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
InnovAge Holding Corp. is covered by 15 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vikram Kesavabhotla | Baird |
| Steven Valiquette | Barclays |
| Sarah James | Barclays |